Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure

William T. Abraham, Brian D Lowes, Michel White, Debra A. Ferguson, Cheri A. Scheffel, Eugene E. Wolfel, Joann Lindenfeld, Michael R. Bristow

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

OPC-18790 (Otsuka America Pharmaceutical, Rockville, MD), a novel positive inotropic agent, produces titratable hemodynamic benefits in patients with advanced heart failure. In such patients, OPC-18790 has been shown to acutely increase the cardiac index, while reducing systemic vascular resistance and left ventricular filling pressure, without an associated increase in heart rate. This study was performed to compare the acute hemodynamic effects of OPC-18790 and the beta-adrenergic receptor agonist, dobutamine, in patients with advanced heart failure. OPC-18790 and dobutamine were compared on successive days in 13 patients with worsening New York Heart Association class III or IV heart failure. The mean (± SEM) left ventricular ejection fraction was 15 ± 2% (range, 6-29%). Pretreatment hemodynamics were: heart rate, 96 ± 2 beats/min; mean arterial pressure, 77 ± 3 mmHg; cardiac index, 1.80 ± 0.10 L/min/m2; pulmonary capillary wedge pressure, 27 ± 1 mmHg; mean pulmonary arterial pressure, 41 ± 2 mmHg; and systemic vascular resistance, 1,732 ± 152 dynes·s/cm5. At infusion rates yielding comparable increases in the cardiac index (5 μg/kg/min for 2 hours for each drug), OPC-18790 produced significantly more favorable effects on heart rate (-2 ± 3% vs 11 ± 4%; P = .01), pulmonary capillary wedge pressure (-32 ± 4% vs -17 ± 8%; P = .04), mean pulmonary arterial pressure (-14 ± 3% vs 6 ± 11%; P = .06), stroke volume index (48 ± 8% vs 29 ± 7%; P = .02), stroke work index (70 ± 11 vs 42% ± 12%; P = .03), and rate pressure product (2 ± 4% vs 14 ± 4%; P = .05). The hemodynamic profile for OPC-18790 differs from dobutamine, with OPC-18790 exhibiting no increase in heart rate, greater preload reduction, and an increase in cardiac performance at a lower estimated metabolic cost.

Original languageEnglish (US)
Pages (from-to)57-62
Number of pages6
JournalJournal of Cardiac Failure
Volume1
Issue number1
DOIs
StatePublished - Jan 1 1994

Fingerprint

Dobutamine
Heart Failure
Hemodynamics
Heart Rate
Arterial Pressure
Pulmonary Wedge Pressure
Vascular Resistance
Stroke Volume
Adrenergic beta-Agonists
Lung
Ventricular Pressure
toborinone
Pharmaceutical Preparations
Stroke
Pressure
Costs and Cost Analysis

Keywords

  • beta-adrenergic
  • inotropic agents
  • quinolinone derivatives
  • receptor agonists

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure. / Abraham, William T.; Lowes, Brian D; White, Michel; Ferguson, Debra A.; Scheffel, Cheri A.; Wolfel, Eugene E.; Lindenfeld, Joann; Bristow, Michael R.

In: Journal of Cardiac Failure, Vol. 1, No. 1, 01.01.1994, p. 57-62.

Research output: Contribution to journalArticle

Abraham, WT, Lowes, BD, White, M, Ferguson, DA, Scheffel, CA, Wolfel, EE, Lindenfeld, J & Bristow, MR 1994, 'Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure', Journal of Cardiac Failure, vol. 1, no. 1, pp. 57-62. https://doi.org/10.1016/1071-9164(94)90008-6
Abraham, William T. ; Lowes, Brian D ; White, Michel ; Ferguson, Debra A. ; Scheffel, Cheri A. ; Wolfel, Eugene E. ; Lindenfeld, Joann ; Bristow, Michael R. / Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure. In: Journal of Cardiac Failure. 1994 ; Vol. 1, No. 1. pp. 57-62.
@article{943ba388ca6a478b9289db535678a7a3,
title = "Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure",
abstract = "OPC-18790 (Otsuka America Pharmaceutical, Rockville, MD), a novel positive inotropic agent, produces titratable hemodynamic benefits in patients with advanced heart failure. In such patients, OPC-18790 has been shown to acutely increase the cardiac index, while reducing systemic vascular resistance and left ventricular filling pressure, without an associated increase in heart rate. This study was performed to compare the acute hemodynamic effects of OPC-18790 and the beta-adrenergic receptor agonist, dobutamine, in patients with advanced heart failure. OPC-18790 and dobutamine were compared on successive days in 13 patients with worsening New York Heart Association class III or IV heart failure. The mean (± SEM) left ventricular ejection fraction was 15 ± 2{\%} (range, 6-29{\%}). Pretreatment hemodynamics were: heart rate, 96 ± 2 beats/min; mean arterial pressure, 77 ± 3 mmHg; cardiac index, 1.80 ± 0.10 L/min/m2; pulmonary capillary wedge pressure, 27 ± 1 mmHg; mean pulmonary arterial pressure, 41 ± 2 mmHg; and systemic vascular resistance, 1,732 ± 152 dynes·s/cm5. At infusion rates yielding comparable increases in the cardiac index (5 μg/kg/min for 2 hours for each drug), OPC-18790 produced significantly more favorable effects on heart rate (-2 ± 3{\%} vs 11 ± 4{\%}; P = .01), pulmonary capillary wedge pressure (-32 ± 4{\%} vs -17 ± 8{\%}; P = .04), mean pulmonary arterial pressure (-14 ± 3{\%} vs 6 ± 11{\%}; P = .06), stroke volume index (48 ± 8{\%} vs 29 ± 7{\%}; P = .02), stroke work index (70 ± 11 vs 42{\%} ± 12{\%}; P = .03), and rate pressure product (2 ± 4{\%} vs 14 ± 4{\%}; P = .05). The hemodynamic profile for OPC-18790 differs from dobutamine, with OPC-18790 exhibiting no increase in heart rate, greater preload reduction, and an increase in cardiac performance at a lower estimated metabolic cost.",
keywords = "beta-adrenergic, inotropic agents, quinolinone derivatives, receptor agonists",
author = "Abraham, {William T.} and Lowes, {Brian D} and Michel White and Ferguson, {Debra A.} and Scheffel, {Cheri A.} and Wolfel, {Eugene E.} and Joann Lindenfeld and Bristow, {Michael R.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1016/1071-9164(94)90008-6",
language = "English (US)",
volume = "1",
pages = "57--62",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure

AU - Abraham, William T.

AU - Lowes, Brian D

AU - White, Michel

AU - Ferguson, Debra A.

AU - Scheffel, Cheri A.

AU - Wolfel, Eugene E.

AU - Lindenfeld, Joann

AU - Bristow, Michael R.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - OPC-18790 (Otsuka America Pharmaceutical, Rockville, MD), a novel positive inotropic agent, produces titratable hemodynamic benefits in patients with advanced heart failure. In such patients, OPC-18790 has been shown to acutely increase the cardiac index, while reducing systemic vascular resistance and left ventricular filling pressure, without an associated increase in heart rate. This study was performed to compare the acute hemodynamic effects of OPC-18790 and the beta-adrenergic receptor agonist, dobutamine, in patients with advanced heart failure. OPC-18790 and dobutamine were compared on successive days in 13 patients with worsening New York Heart Association class III or IV heart failure. The mean (± SEM) left ventricular ejection fraction was 15 ± 2% (range, 6-29%). Pretreatment hemodynamics were: heart rate, 96 ± 2 beats/min; mean arterial pressure, 77 ± 3 mmHg; cardiac index, 1.80 ± 0.10 L/min/m2; pulmonary capillary wedge pressure, 27 ± 1 mmHg; mean pulmonary arterial pressure, 41 ± 2 mmHg; and systemic vascular resistance, 1,732 ± 152 dynes·s/cm5. At infusion rates yielding comparable increases in the cardiac index (5 μg/kg/min for 2 hours for each drug), OPC-18790 produced significantly more favorable effects on heart rate (-2 ± 3% vs 11 ± 4%; P = .01), pulmonary capillary wedge pressure (-32 ± 4% vs -17 ± 8%; P = .04), mean pulmonary arterial pressure (-14 ± 3% vs 6 ± 11%; P = .06), stroke volume index (48 ± 8% vs 29 ± 7%; P = .02), stroke work index (70 ± 11 vs 42% ± 12%; P = .03), and rate pressure product (2 ± 4% vs 14 ± 4%; P = .05). The hemodynamic profile for OPC-18790 differs from dobutamine, with OPC-18790 exhibiting no increase in heart rate, greater preload reduction, and an increase in cardiac performance at a lower estimated metabolic cost.

AB - OPC-18790 (Otsuka America Pharmaceutical, Rockville, MD), a novel positive inotropic agent, produces titratable hemodynamic benefits in patients with advanced heart failure. In such patients, OPC-18790 has been shown to acutely increase the cardiac index, while reducing systemic vascular resistance and left ventricular filling pressure, without an associated increase in heart rate. This study was performed to compare the acute hemodynamic effects of OPC-18790 and the beta-adrenergic receptor agonist, dobutamine, in patients with advanced heart failure. OPC-18790 and dobutamine were compared on successive days in 13 patients with worsening New York Heart Association class III or IV heart failure. The mean (± SEM) left ventricular ejection fraction was 15 ± 2% (range, 6-29%). Pretreatment hemodynamics were: heart rate, 96 ± 2 beats/min; mean arterial pressure, 77 ± 3 mmHg; cardiac index, 1.80 ± 0.10 L/min/m2; pulmonary capillary wedge pressure, 27 ± 1 mmHg; mean pulmonary arterial pressure, 41 ± 2 mmHg; and systemic vascular resistance, 1,732 ± 152 dynes·s/cm5. At infusion rates yielding comparable increases in the cardiac index (5 μg/kg/min for 2 hours for each drug), OPC-18790 produced significantly more favorable effects on heart rate (-2 ± 3% vs 11 ± 4%; P = .01), pulmonary capillary wedge pressure (-32 ± 4% vs -17 ± 8%; P = .04), mean pulmonary arterial pressure (-14 ± 3% vs 6 ± 11%; P = .06), stroke volume index (48 ± 8% vs 29 ± 7%; P = .02), stroke work index (70 ± 11 vs 42% ± 12%; P = .03), and rate pressure product (2 ± 4% vs 14 ± 4%; P = .05). The hemodynamic profile for OPC-18790 differs from dobutamine, with OPC-18790 exhibiting no increase in heart rate, greater preload reduction, and an increase in cardiac performance at a lower estimated metabolic cost.

KW - beta-adrenergic

KW - inotropic agents

KW - quinolinone derivatives

KW - receptor agonists

UR - http://www.scopus.com/inward/record.url?scp=0028521264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028521264&partnerID=8YFLogxK

U2 - 10.1016/1071-9164(94)90008-6

DO - 10.1016/1071-9164(94)90008-6

M3 - Article

VL - 1

SP - 57

EP - 62

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 1

ER -